PANO1 and Miyoshi myopathy: HDACi as monotherapy demonstrated only a modest clinical benefit, but rationally designed combination of PANO-BTZ-DEX in PANORAMA studies demonstrated a survival benefit in relapsed and/or refractory MM (particularly among those with at least two prior regimens including BTZ and IMiD).